Akari Therapeutics Plc
For the period ended Mar 31, 2025. Filed May 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 14, 2025
AKTX$7.13-6.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(amounts in thousands)
| Three Months Ended | ||
|---|---|---|
| March 31, | ||
| 2025 | 2024 | |
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||
| Net loss | $(3,705) | $(5,566) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | — | 13 |
| Stock-based compensation | 1,015 | 296 |
| Gain on debt extinguishment | (54) | — |
| Change in fair value of warrant liabilities | 54 | (649) |
| Unrealized foreign currency exchange (gains) losses | (27) | 264 |
| Change in assets and liabilities: | ||
| Prepaid expenses and other current assets | 84 | 138 |
| Accounts payable and accrued expenses | 483 | 1,460 |
| Net cash used in operating activities | (2,150) | (4,044) |
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||
| Proceeds from issuance of shares, net of issuance costs | 1,557 | 1,726 |
| Proceeds from employee vesting of restricted shares | — | 3 |
| Proceeds from deposits received for share subscriptions | 1,090 | — |
| Repayments of notes payable | (406) | — |
| Payments on short-term financing arrangement | (108) | (215) |
| Net cash provided by financing activities | 2,133 | 1,514 |
| Effect of exchange rates on cash | — | (5) |
| Net change in cash | (17) | (2,535) |
| Cash and restricted cash at beginning of period | 2,659 | 3,845 |
| Cash and restricted cash at end of period | $2,642 | $1,310 |
| Components of cash and restricted cash | ||
| Cash | $2,582 | $1,310 |
| Restricted cash | 60 | — |
| Total cash and restricted cash | $2,642 | $1,310 |
| SUPPLEMENTAL DISCLOSURES OF NONCASH ACTIVITIES: | ||
| Financing costs in accrued expenses | $315 | $62 |
| Financing costs, deposits received for share subscriptions in accounts payable | $140 | $— |
| Issuance of share capital for settlement of related party debt | $1,000 | $— |
| Seller-financed purchases | $499 | $1,105 |
| SUPPLEMENTAL CASH FLOW DISCLOSURES: | ||
| Cash paid for interest | $7 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.